What are the recent trends in market size and growth for the donepezil market?
The donepezil market size has grown strongly in recent years. It will grow from $1.00 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to the increasing prevalence of Alzheimer’s disease, the growing geriatric population, the rise in government spending and programs, the rising awareness of neurodegenerative disorders, and the rise in demand for high-quality nucleic acid samples.
The donepezil market size is expected to see steady growth in the next few years. It will grow to $1.27 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to rising healthcare expenditure, increasing focus on early diagnosis of Alzheimer’s, growing demand for combination therapies, growing investment in healthcare infrastructure, and growing consciousness about neurodegenerative illnesses. Major trends in the forecast period include innovations in drug formulations and delivery methods, technological advancements, the launch of novel dosage forms and formulations, the approval of generic versions of donepezil, and advanced research facilities.
Get Your Free Sample of The Global Donepezil Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21174&type=smp
How have varous drivers impacted the growth of the donepezil market?
The increasing prevalence of alzheimer’s disease is expected to propel the growth of the donepezil market going forward. Alzheimer’s disease is a progressive neurological disorder that causes the degeneration and death of brain cells, leading to memory loss, cognitive decline, and behavioral changes. The Alzheimer’s disease cases are increasing due to several reasons, such as an aging population, population growth, lifestyle-related factors, an increase in chronic diseases, genetic factors, and environmental exposures. Donepezil serves as an effective symptomatic treatment for Alzheimer’s disease by enhancing cognitive function and daily living skills through its action on acetylcholine levels in the brain. For instance, in May 2024, according to a report by the Alzheimer’s Association, a US-based nonprofit organization dedicated to Alzheimer’s care, support, and research, the number of Americans aged 65 and older diagnosed with Alzheimer’s dementia rose from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the rising incidence of alzheimer’s is driving the growth of the donepezil market.
What are the primary segments of the donepezil market?
The donepezil market covered in this report is segmented –
1) By Type: 5mg, 10mg, 23mg
2) By Route Of Administration: Oral, Transdermal
3) By Application: Hospitals, Clinics, Drugstore
Subsegments:
1) By 5mg: Immediate-Release 5mg, Orally Disintegrating 5mg
2) By 10mg: Immediate-Release 10mg, Orally Disintegrating 10mg
3) By 23mg: Extended-Release 23mg, Film-Coated 23mg
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/donepezil-global-market-report
Which firms are leading the donepezil market?
Major companies operating in the donepezil market are AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Inc., Intas Pharmaceuticals Ltd., Mylan NV, Sandoz Group AG, Hetero Drugs Ltd., Sun Pharmaceutical Inc., Eisai Co. Ltd., Cipla Ltd., Dr Reddy’s Laboratories, Apotex Inc., H Lundbeck A/S, Zydus Cadila, Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd, Alkem Laboratories Ltd., Jubilant Pharmova Ltd., Wockhardt Ltd., Luoxin Pharmaceuticals Group
How will industry trends affect the trajectory of the donepezil market?
Major companies operating in the donepezil market are focusing on developing new advanced technologies such as the donepezil system, to improve patient compliance and enhance the effectiveness of treatment through innovative formulations like extended-release. Donepezil is a system to the pharmacological system or mechanism of action of donepezil, which is a medication primarily used for treating Alzheimer’s disease and other forms of dementia. For instance, in October 2022, Corium Innovation Inc., a US-based biopharmaceutical company, launched a donepezil transdermal system (Adlarity) to treat patients with mild, moderate, or severe Alzheimer disease (AD) dementia. The new transdermal formulation of donepezil delivers the medication directly through the skin, bypassing the digestive system. This approach significantly reduces the likelihood of gastrointestinal side effects and offers a more convenient method of administration, benefiting both patients with Alzheimer’s disease and their caregivers.
Which geographic trends are shaping the donepezil market, and which region has the highest market share?
North America was the largest region in the donepezil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the donepezil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Donepezil Market Report 2025 Offer?
The donepezil market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Donepezil refers to a medication used to treat symptoms of Alzheimer’s disease by inhibiting the breakdown of acetylcholine, a neurotransmitter important for memory and cognition. It works as a cholinesterase inhibitor, improving cognitive function and slowing the progression of symptoms in patients with mild to moderate Alzheimer’s disease.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21174
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
